ABBV-711

Phase 1Small molecule

AbbVie

ABBV-711 is one of 2 small molecule programs targeting Advanced Squamous Tumors. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Advanced Squamous TumorsRecruiting

Advanced Squamous TumorsPhase 1

Recruiting

Competition

Competitive Landscape

1 competitor in Advanced Squamous Tumors

#DrugCompanyPhaseTrials

Budigalimab

AbbVie

Phase 1

1 2

ABBV-711

AbbVie

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2030

Phase 1Recruiting

Advanced Squamous Tumors

NCT07241039

Clinical

Trials by Indication[1]

Advanced Squamous Tumors1 trial

A Phase 1 First-in-Human, Open-Label Study Evaluating the Safety, Pharmacokinetics, and Efficacy of ABBV-711 as a Monotherapy or in Combination With Budigalimab (ABBV-181) in Adult Subjects With Advanced Squamous Tumors

Recruiting· AbbVie logo

AbbVie·Phase 1·NCT07241039·220 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for ABBV-711. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ABBV-711 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ABBV-711. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — AbbVie company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: AbbVie

ABBV-711

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2030

Trials by Indication[1]

Advanced Squamous Tumors1 trial

References

Drug Info

Quick Facts

Related News